BTIG Rates Glaukos (GKOS) buy, $162 Price Target
BTIG reiterated its buy rating on Glaukos Corporation (NYSE: GKOS) and set a price target of $162, a 30.41% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
BTIG rated Glaukos Corporation ($GKOS) "buy" with a $162 price target on June 10, 2026.
Since the rating, $GKOS is up 4.0% after 1 week, up 24.7% after 1 month and up 34.6% to date (from the $122.49 close on Jun 10, 2026).
GKOS
Glaukos Corporation
Key Points
- On June 10, 2026, BTIG reaffirmed its buy rating on Glaukos Corporation (NYSE: GKOS) with a price target of $162, as the stock trades at $124.22.
- BTIG's $162 price target implies 30.41% upside from Glaukos Corporation's ($GKOS) current $124.22 share price.
- Glaukos, which focuses on medical devices for eye care, has seen its stock trade between $73.16 and $191.62 over the past year.
- Currently, 12 analysts have opinions on Glaukos, with an average price target of $197.75.
Get $GKOS trade alerts by text
We text you when insiders, Congress or big funds trade $GKOS. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Glaukos Corporation alert may contain errors. Disclosures
BTIG's Rating on Glaukos Corporation
On June 10, 2026, BTIG reiterated its buy rating on Glaukos Corporation (NYSE: GKOS) with a price target of $162. As of this announcement, the stock was trading at $124.22.
What's the Change in Rating?
The BTIG rating remains unchanged, maintaining a buy stance on Glaukos. The new price target of $162 reflects the firm's confidence in the company's future growth.
Other Analyst Ratings
Glaukos Corporation has received positive feedback from various analysts. On October 12, 2026, BTIG maintained a buy rating with a price target of $205. Jefferies also upheld a buy rating with a target of $210 on September 22, 2026. On August 20, 2026, BTIG again confirmed a buy rating, this time with a target of $202. Other firms, like UBS, have been more cautious, rating it as Neutral with a target of $172.
Stock Performance Context
Glaukos Corporation's stock trades well below its 52-week high of $191.62, indicating a potential opportunity for growth. With a market cap of approximately $9.5 billion, the company's stock has shown volatility within a range of $73.16 to $191.62 in the past year. Investors might consider this as they evaluate Glaukos’ stock performance.
$GKOS price target
Glaukos Corporation daily closes and this analyst's $162 target. Not advice.
Recent Earnings
In its latest fiscal year, Glaukos reported revenue of about $612.8 million, marking a growth rate of 49.5%. However, the company faced challenges, reporting an EPS of -$3.28 and a net margin of -30.7%. The next earnings call is scheduled for October 28, 2026, which could provide insights into its financial health.
What GKOS Does
Glaukos Corporation, based in Aliso Viejo, California, develops medical technologies for treating eye conditions, particularly glaucoma. Its innovative products like the iStent micro-bypass stents aim to improve patient outcomes in eye care.
What to Watch at GKOS
Investors should keep an eye on Glaukos’s upcoming earnings report on October 28, 2026, as it may provide more information on the company's performance and growth trajectory. The latest analyst ratings suggest a cautiously optimistic outlook as the stock is currently trading below its historical highs.
Related Filing Alerts
Source: BTIG's rating change on $GKOS (Jun 10, 2026). Written by software, not financial advice. How we make alerts